Omalizumab add-on therapy significantly reduces asthma exacerbations in patients with inadequately controlled severe persistent asthma despite GINA 2002 step 4 therapy: INNOVATE

Omalizumab add-on therapy significantly reduces asthma exacerbations in patients with inadequately controlled severe persistent asthma despite GINA 2002 step 4 therapy: INNOVATE

Patients with inadequately controlled severe persistent asthma despite GINA 2002 step 4 therapy (high-dose inhaled corticosteroids [ICS] plus long-acting β2-agonists [LABA] and additional controller medication if required) are a challenging population with a significant unmet medical need.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of allergy and clinical immunology 2005-02, Vol.115 (2), p.S76-S76
Hauptverfasser: Korenblat, P., Levy, R., Slavin, R., Hedgecock, S., Fox, H., Surrey, K.
Format: Artikel
Sprache:eng
Schlagworte:
Asthma
Drug therapy
Medical research
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Patients with inadequately controlled severe persistent asthma despite GINA 2002 step 4 therapy (high-dose inhaled corticosteroids [ICS] plus long-acting β2-agonists [LABA] and additional controller medication if required) are a challenging population with a significant unmet medical need.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2004.12.319